MSD
MSD’s interim Keytruda combo data spooks Roche and BMS
January 16, 2018Research and Development MSD, Merck, biotech, drugs, keytruda, pharma, pharmaceutical
When PD-1/L1 treatments first came on the market, there was a race to snaffle as many indications as possible for …
AZ and MSD’s Lynparza becomes first PARP inhibitor approved in US for metastatic breast cancer
January 15, 2018Sales and Marketing AstraZeneca, Cancer, FDA, MSD, breast cancer, lynparza, pharma
The FDA has announced that it has awarded marketing authorisation in the US to Lynparza (olaparib), a poly ADP-ribose polymerase …
Pharmafile.com’s top ten stories of 2017
December 22, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Abbott, Actelion, Amgen, AstraZeneca, Cyber attack, EMA, European Commission, Humira, J&J, JJ, Johnson & Johnson, MSD, Sanofi, Shire, Teva, biosimilar, brexit
After a packed year that has flown by, we’ve reached the final top ten of 2017. Below you can find …
MSD and Pfizer receive approval for combo diabetes therapy
December 21, 2017Sales and Marketing MSD, Pfizer, biotech, diabetes, drugs, pharma, pharmaceutical
MSD (known as Merck in North America) and Pfizer have announced that their sodium-glucose co-transporter 2 (SGLT2) inhibitor has received …
Keytruda falls hard at gastric cancer hurdle
December 18, 2017Research and Development, Sales and Marketing MSD, biotech, drugs, keytruda, pharma, pharmaceutical
There was a time when PD-1/L1 immunotherapy treatments could do no wrong, blasting through indication after indication. However, the limits …
UK government unveils pharma research HQ coup
November 27, 2017Medical Communications, Sales and Marketing MSD, biotech, drugs, life sciences, pharma, pharmaceutical
The UK government’s Autumn Budget struck a gloomy note for the economy, with figures pointing towards low productivity and the …
MSD withdraws European application of Keytruda combo in lung cancer
October 30, 2017Sales and Marketing EMA, MSD, keytruda
MSD has been forced to withdraw its EU marketing application for Keytruda (pembrolizumab) in combination with pemetrexed and carboplatin as …
Samsung Biologics reinforces biologic manufacturing and development partnership with MSD
October 30, 2017Manufacturing and Production, Sales and Marketing Korea, MSD, Samsung BioLogics, pharma
Samsung Biologics has announced it has expanded its strategic alliance with MSD, or Merck as it is known in the …
MSD cuts 1,800 jobs in US operations restructure
October 23, 2017Manufacturing and Production, Sales and Marketing MSD, Merck, job cuts, pharma
MSD has revealed its intention to cut 1,800 sales positions from its workforce in the US. Across the total number, …
MSD gives up on cholesterol drug, despite positive results
October 12, 2017Medical Communications, Sales and Marketing MSD, Merck, biotech, cholesterol, drugs, pharma, pharmaceutical
MSD, known as Merck in North America, has revealed that it will not pursue a regulatory filing for its cholesterol …
MSD pulls out of hep C space to Gilead’s relief
October 2, 2017Sales and Marketing MSD, biotech, drugs, hepatitis C, pharma, pharmaceutical
MSD, known as Merck in North America, has announced that it will curtail its attempts to make an impact in …
MSD plays catch up with €464m deal for fledgling biotech
September 7, 2017Sales and Marketing Bristol-Myers Squibb, MSD, biotech, drugs, keytruda, pharma, pharmaceutical
MSD has announced that it will acquire Rigontec, a three-year old German biotech, in a deal worth an initial €115 …
Has Trump’s power over pharma come to an end after Charlottesville?
August 31, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Donald Trump, J&J, JJ, Kenneth Frazier, MSD, President trump, Trump, life sciences, medicine, pharma, pharmaceuticals, president
In a shock move that was to have deeply resonant consequences, MSD Chairman and Chief Executive Officer Kenneth Frazier announced …
The September 2017 issue of Pharmafocus is now live!
August 30, 2017Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Cancer, Cancer Research UK, MSD, Pharmafocus, President trump, Takeda, Trump, charlottesville, life sciences, oncology, pharmaceuticals, phatma
The September edition of Pharmafocus is now available – click here to read online.
MSD scores trial success in reducing cardiovascular risk
August 29, 2017Manufacturing and Production, Research and Development MSD, heart attack, heart disease, life sciences, pharma, pharmaceutical
New data on MSD’s anacetrapib has revealed that the drug was able to reduce risk of the risk of major …
Latest content
Pharma sees climate disruption as growing supply-chain risk
Manchester NHS-MHRA partnership to test new technologies in real-world care
